Products
Online Inquiry
Axitinib
Cat. No.:
0225LY-0765
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Axitinib is a multi-targeted tyrosine kinase inhibitor used for treating renal cell carcinoma; it inhibits PDGFR-beta and VEGFR1, 2, and 3 with IC50 values of 2, 4, 20, and 0.4 nM, respectively.
Synonym:
319460-85-0; (E)-N-Methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
CAS No.:
319460-85-0
Compound CID:
6450551
Formula:
C22H18N4OS
Formula Weight:
386.47
Specification
Targets&IC50:
PDGFRβ: 1.6 nM; c-Kit: 1.7 nM; VEGFR1/FLT1: 0.1 nM; VEGFR2/KDR: 0.2 nM; VEGFR2/Flk1: 0.18 nM; VEGFR3: 0.1-0.3 nM
Relative Density:
1.35 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Axitinib can be used in angiogenesis research to study the selective inhibition of VEGFR-1, -2, and -3 in various malignant tumors.
Library Information
Target:
c-Kit; PDGFR; VEGFR
Receptor:
c-kit; PDGFRβ; VEGFR1; VEGFR2; VEGFR3
Pathways:
Tyrosine kinase/adaptors; Angiogenesis
Plate Number:
AOCL-10
Plate Location:
h2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
23.2 mg/mL; 60.03 mM
ALogP:
4.492
HBA_Count:
3
HBD_Count:
2
Rotatable Bond:
5
